HXN-2010 / Earendil Labs - LARVOL DELTA

An AI-Guided Biparatopic DLL3-Targeting ADC Demonstrates Enhanced Preclinical Efficacy (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

ADC • Preclinical • Oncology • DLL3

An AI-guided biparatopic DLL3-targeting ADC demonstrates enhanced preclinical efficacy (AACR 2026) - "The ADC showed potent cytotoxicity across multiple DLL3-expressing cell lines and achieved significant tumor suppression in CDX models. Toxicological studies revealed a favorable safety profile in both transgenic mice and non-human primates.Conclusion This biparatopic ADC represents a promising therapeutic candidate for DLL3-expressing tumors, demonstrating enhanced efficacy and favorable preclinical safety compared to previous approaches."

ADC • Preclinical • Endocrine Cancer • Lung Cancer • Neuroendocrine Neoplasm • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3